TAS6417 is primarily investigated for its potential therapeutic application in cancer treatment, specifically as a selective agonist of the GPRC5D receptor. This receptor is overexpressed in certain hematologic malignancies, including multiple myeloma, making it a promising target for immunotherapy. TAS6417 facilitates targeted immune responses by activating GPRC5D-expressing cells, which can lead to the destruction of malignant plasma cells. Due to its selectivity, it may offer a favorable safety profile with reduced off-target effects compared to conventional therapies. It is being explored in clinical development for relapsed or refractory multiple myeloma, where treatment options are limited and new targeted agents are urgently needed.